⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084273 | 0.87 | — | — | |
| SCHEMBL17221437 | 0.87 | — | — | |
| SCHEMBL3610059 | 0.83 | — | — | |
| SCHEMBL11575988 | 0.67 | — | — | |
| SCHEMBL3445941 | 0.67 | — | — | |
| SCHEMBL9713610 | 0.67 | — | — | |
| SCHEMBL11422206 | 0.67 | ALDH1A1 (0.39) | — | |
| SCHEMBL1188701 | 0.67 | — | — | |
| SCHEMBL9321529 | 0.65 | — | — | |
| SCHEMBL11239529 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |